Anthony J. Olszanski, MD, RPh
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Interim Chair, Hematology/Oncology
Director, Early Clinical Drug Development Phase 1 Program
Co-Director, Cutaneous Oncology and Melanoma Program
Early Clinical Drug Development/Phase 1 Trials; Melanoma and skin cancer; Lung cancers; Gastrointestinal cancers
I believe that the path towards treating any disease is best navigated by thoroughly understanding not only the disease, but also the patient. Good communication between a physician and a patient is especially critical in the treatment of cancer. Each patient has a right to be both respected and heard. In addition, relying on a team of experts to help manage the complexities of treating cancer is essential for success. As a physician, I strive to provide personalized and scientifically sound care to each of my patients.
My medical career started out as a pharmacist, specializing in oncology, where I prepared chemotherapy regimens and studied the effects the body has on drugs (pharmacokinetics). When I went to medical school, it was for the sole purpose of eventually becoming an oncologist. During my hematology/oncology and clinical pharmacology fellowships, I spent a great deal of time in early clinical development, with a goal of finding new effective therapies for patients with cancer. I honed my knowledge of drug discovery by spending five years in the pharmaceutical industry where I led multiple programs aimed at treating patients with cancers that didn’t respond to traditional chemotherapy. Today, my interests focus on early drug development for all types of cancers, and understanding how each medication may best be used. In addition I specifically focus on the treatment of lung cancer, skin cancers including melanoma, and gastrointestinal malignancies.
In many situations, the best medical care a patient with cancer can get is on a clinical trial. These clinical trials offer patients potentially promising new therapies and very close follow up supplied by a team of experts. Fox Chase Cancer Center, with its leading-edge technology and dedicated medical professionals, offers numerous clinical trials and is helping to advance the care of all patients with cancer.
The staff at Fox Chase Cancer Center continually impress me with their unified commitment towards reducing the burden of cancer. When you step through the doors at Fox Chase Cancer Center, it is obvious that focusing on the patient is the top priority. I am proud to be a member of the caring community at FCCC, where oncology research and science is tailored and personalized for each patient.
- Fellowship, Clinical Pharmacology/Toxicology Fellowship, Oncology Phase I Program, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 2002-2004
- Fellowship, Hematology/Oncology Fellowship, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 1999-2002
- Residency, Internal Medicine, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 1996-1999
- Biostatistics, Dartmouth Medical School Center for Evaluative Clinical Sciences, Hanover, NH 2003
- MD, University of Medicine and Dentistry of New Jersey, Newark, NJ, 1996
- BS Pharmacy, University of Montana, Missoula, MT, 1990
- Board certified in Medical Oncology
- Board certified in Clinical Pharmacology
- National Comprehensive Cancer Network (NCCN)
- International Program Steering Committee
- Melanoma Panel
- NCCN ORP Investigator Steering Committee
- American Board of Clinical Pharmacology
- American Society of Clinical Oncology
Honors & Awards
- Robert L. Krigel memorial award: Excellence in teaching and clinical oncology, 2014
It sounds like something out of a movie.
Although she was under twilight anesthesia, Mary Carr could hear the doctors talking during her colonoscopy in May 2011. “I couldn’t feel anything but I heard them talking about the Phillies,” Mary recalls. “All of a sudden I hear one of them say, ‘There’s something there, I can’t go any further. The other one said, ‘Is it cancer?’ “What range is she?’ 'Two to four.' I heard everything. When they wheeled me out, I said to the nurse, 'So I have colon cancer?'”
In November 2011, Donna Piunt was driving along to work like any other 51-year-old, jamming to music in her car. She and her husband, Stefan, were happily married and they had two beautiful daughters in their twenties. Donna arrived to work with a smile on her face as she greeted the little boy she cared for a nanny. In her spare time, she was pursuing her Associate’s Degree in medical billing and coding, which she could work on while the little boy napped.
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, et al. Investigational new drugs. 2015; 33(5):1040-7. PubMed
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, et al. Anti-cancer drugs. 2015; 26(7):785-92. PubMed
Principles of immunotherapy. Olszanski AJ. Journal of the National Comprehensive Cancer Network : JNCCN. 2015; 13(5 Suppl):670-2. PubMed